Amneal Pharmaceuticals Inc

AMRX is in a Stage 4 decline with failed support signaling bearish medium-term bias, reinforced by price trading below declining EMAs and the 50-day SMA. Despite an Oversold reading, no meaningful reversal structure or exhaustion is visible. Failed rallies into resistance near 17.3–17.6 confirm seller control. Selling into resistance now aligns with the Growth at Reasonable Price framework.

• ↑Q2 revenue $796M (+10% YoY); adjusted EBITDA $206M (+12% YoY).
• ↑Specialty segment sales $149M (+17% YoY); adjusted EPS $0.30 (+20%).
• ↓P/E 37.6x vs. pharma peer average 16x risks multiple compression.